Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N.

Science. 2010 Oct 8;330(6001):228-31. doi: 10.1126/science.1196333. Epub 2010 Sep 8.

2.

Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.

Huang HN, Lin MC, Huang WC, Chiang YC, Kuo KT.

Mod Pathol. 2014 Jul;27(7):983-90. doi: 10.1038/modpathol.2013.216. Epub 2013 Dec 13.

3.

ARID1A mutations in endometriosis-associated ovarian carcinomas.

Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih IeM, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG.

N Engl J Med. 2010 Oct 14;363(16):1532-43. doi: 10.1056/NEJMoa1008433. Epub 2010 Sep 8.

4.

Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.

Chandler RL, Damrauer JS, Raab JR, Schisler JC, Wilkerson MD, Didion JP, Starmer J, Serber D, Yee D, Xiong J, Darr DB, Pardo-Manuel de Villena F, Kim WY, Magnuson T.

Nat Commun. 2015 Jan 27;6:6118. doi: 10.1038/ncomms7118.

5.

PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.

Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O.

Virchows Arch. 2012 Jan;460(1):77-87. doi: 10.1007/s00428-011-1169-8. Epub 2011 Nov 26.

PMID:
22120431
6.

PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.

Rahman M, Nakayama K, Rahman MT, Nakayama N, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Otsuki Y, Nakayama S, Miyazaki K.

Anticancer Res. 2013 Jan;33(1):113-8.

PMID:
23267135
7.

ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.

Guan B, Wang TL, Shih IeM.

Cancer Res. 2011 Nov 1;71(21):6718-27. doi: 10.1158/0008-5472.CAN-11-1562. Epub 2011 Sep 7. Erratum in: Cancer Res. 2012 Jun 15;72(12):3116.

8.

Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma.

Maeda D, Mao TL, Fukayama M, Nakagawa S, Yano T, Taketani Y, Shih IeM.

Int J Mol Sci. 2010;11(12):5120-8. doi: 10.3390/ijms11125120. Epub 2010 Dec 13.

9.
10.

The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.

Goldman AR, Bitler BG, Schug Z, Conejo-Garcia JR, Zhang R, Speicher DW.

Mol Cell Proteomics. 2016 Nov;15(11):3348-3360. Epub 2016 Sep 21.

11.

ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.

Samartzis EP, Noske A, Dedes KJ, Fink D, Imesch P.

Int J Mol Sci. 2013 Sep 12;14(9):18824-49. doi: 10.3390/ijms140918824. Review.

12.

Inactivating mutations in SWI/SNF chromatin remodeling genes in human cancer.

Oike T, Ogiwara H, Nakano T, Yokota J, Kohno T.

Jpn J Clin Oncol. 2013 Sep;43(9):849-55. doi: 10.1093/jjco/hyt101. Epub 2013 Jul 30.

PMID:
23904343
13.

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.

Miller RE, Brough R, Bajrami I, Williamson CT, McDade S, Campbell J, Kigozi A, Rafiq R, Pemberton H, Natrajan R, Joel J, Astley H, Mahoney C, Moore JD, Torrance C, Gordan JD, Webber JT, Levin RS, Shokat KM, Bandyopadhyay S, Lord CJ, Ashworth A.

Mol Cancer Ther. 2016 Jul;15(7):1472-84. doi: 10.1158/1535-7163.MCT-15-0554. Epub 2016 Jun 30.

14.

Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.

Wu RC, Ayhan A, Maeda D, Kim KR, Clarke BA, Shaw P, Chui MH, Rosen B, Shih IeM, Wang TL.

J Pathol. 2014 Mar;232(4):473-81. doi: 10.1002/path.4315.

15.

Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.

Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O.

Mod Pathol. 2012 Apr;25(4):615-24. doi: 10.1038/modpathol.2011.189. Epub 2011 Dec 9.

16.

Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types.

Jones S, Li M, Parsons DW, Zhang X, Wesseling J, Kristel P, Schmidt MK, Markowitz S, Yan H, Bigner D, Hruban RH, Eshleman JR, Iacobuzio-Donahue CA, Goggins M, Maitra A, Malek SN, Powell S, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N.

Hum Mutat. 2012 Jan;33(1):100-3. doi: 10.1002/humu.21633. Epub 2011 Nov 23.

17.

Molecular status of PI3KCA, KRAS and BRAF in ovarian clear cell carcinoma: an analysis of 63 patients.

Zannoni GF, Improta G, Pettinato A, Brunelli C, Troncone G, Scambia G, Fraggetta F.

J Clin Pathol. 2016 Dec;69(12):1088-1092. doi: 10.1136/jclinpath-2016-203776. Epub 2016 May 6.

PMID:
27153872
18.

Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis.

Maru Y, Tanaka N, Ohira M, Itami M, Hippo Y, Nagase H.

Gynecol Oncol. 2017 Feb;144(2):377-383. doi: 10.1016/j.ygyno.2016.11.045. Epub 2016 Dec 9.

PMID:
27939411
19.

A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.

Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS.

BMC Cancer. 2014 Feb 22;14:120. doi: 10.1186/1471-2407-14-120.

20.

ARID1A gene mutation in ovarian and endometrial cancers (Review).

Takeda T, Banno K, Okawa R, Yanokura M, Iijima M, Irie-Kunitomi H, Nakamura K, Iida M, Adachi M, Umene K, Nogami Y, Masuda K, Kobayashi Y, Tominaga E, Aoki D.

Oncol Rep. 2016 Feb;35(2):607-13. doi: 10.3892/or.2015.4421. Epub 2015 Nov 16. Review.

Supplemental Content

Support Center